Repligen Corp
RGEN: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|>y | LOCK|w?fp> | LOCK|&@!lTBn |
Repligen Earnings: Strong Start to the Year, Excellent Margin Expansion
Repligen reported year-over-year organic revenue growth of 11% and adjusted EBITDA margin of 20.6%, an expansion of 130 basis points. For 2026, management reiterated guidance for organic revenue growth of 9% to 13% and raised guidance for adjusted EBITDA margin by 30 basis points to 20.3 to 20.8%.
